Clinical Trial Update: Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and immunogenicity of a 13-valent pneumococcal polysaccharide conjugate vaccine; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13)

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Pneumococcal Infections | Phase 1 | Status: COMPLETED